BioCentury | Oct 19, 2018
Clinical News

Transgene brings IV oncolytic virus into the clinic for GI tumors

...5-FU) chemotherapy prodrug in patients with gastrointestinal tumors. TG6002's viral vector expresses the Saccharomyces cerevisiae FCY1-FUR1 fusion gene ( Saccharomyces cerevisiae FCU1...
...France Product: TG6002 Business: Cancer Molecular target: NA Description: Viral vector expressing the Saccharomyces cerevisiae FCY1-FUR1 fusion gene ( Saccharomyces cerevisiae FCU1...
...tumors Endpoint: Safety and objective response rate (ORR) Status: Phase I/II started Milestone: NA Allison Johnson TG6002 Transgene S.A. Saccharomyces cerevisiae FCY1-FUR1 fusion gene (Saccharomyces cerevisiae FCU1) Gastrointestinal...
BioCentury | Jun 29, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

...hepatocellular carcinoma (HCC) and other liver cancers. Second Military Medical University Distillery Therapeutics Solid tumors Saccharomyces cerevisiae FCY1-FUR1 fusion gene...
Items per page:
1 - 2 of 2